Atgam ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
60Aplastic anemia3

60. Aplastic anemia


Clinical trials : 245 Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05049668
(ClinicalTrials.gov)
October 202113/9/2021RACE 2: a Long Term Follow-up of Patients Participating in the RACE TrialLong-term Follow-up of Patients Participating in RACE: the Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia PatientsSevere Aplastic AnemiaDrug: ATGAM plus CsA with or without EltrombopagEuropean Society for Blood and Marrow TransplantationNULLEnrolling by invitationN/AN/AAll197France
2NCT00944749
(ClinicalTrials.gov)
July 200922/7/2009Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA TreatmentHorse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA TreatmentAnemia, Aplastic;Anemia, HypoplasticDrug: h-ATG (ATGAM );Drug: Cyclosporine (Gengraf )National Heart, Lung, and Blood Institute (NHLBI)NULLCompleted2 Years82 YearsAll23Phase 2United States
3EUCTR2021-002155-11-Outside-EU/EEA
(EUCTR)
09/06/2021Open-label, single-arm, multicenter study in Japanese patients with aplastic anemiaA MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO ACCESS THE EFFICACY AND SAFETY OF PF-06462700 ADMINISTERED INTRAVENOUSLY AT 40 MG/KG/DAY FOR 4 DAYS IN JAPANESE PARTICIPANTS WITH MODERATE AND ABOVE APLASTIC ANEMIA Moderate and above aplastic anemia;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]Trade Name: Atgam
Product Name: Atgam
INN or Proposed INN: Anti-human T-lymphocyte immunoglobulin from horse
Other descriptive name: anti-human immunoglobulin, equine
Pfizer Inc.NULLNAFemale: yes
Male: yes
Phase 3Japan